GBT’s AI-Driven, Human Vitals qTerm Device Patent Received Notice of Allowance

Rhea-AI Summary

GBT Technologies Inc. (GTCH) announced that its non-provisional patent application for the qTerm AI-driven human vitals device has received a notice of allowance, with the patent expected to be granted soon. The device, designed to measure human vitals such as body temperature, blood oxygen, and heart rate through a user-friendly interface, aims to revolutionize personal healthcare and telemedicine. Accompanied by a mobile app and web application, qTerm will allow users to access their health data remotely. However, the company acknowledges potential challenges in raising capital and establishing partnerships for production and distribution.

Positive

• Patent application for qTerm received notice of allowance, expected to be granted soon.
• First release of qTerm planned to include vital measurements like body temperature and heart rate.
• Potential for telemedicine integration and remote user data access.

Negative

• No guarantee of successful product development or regulatory approval.
• Need to raise adequate capital to support research and development.

The patent is expected to be granted in the next few months and protects advanced electronics vital device; AI controlled

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”) AI-Driven, human vitals device, non-provisional patent application, received a notice of allowance and expected to be granted in the next upcoming months. qTerm non-provisional patent was filed on August 3, 2020, application #16/983,289 and covers an electronic health device to measure human vitals with a touch of a finger, internal project name qTerm. GBT completed the development of a fully working prototype in 2022 including robust testing, debugging and participant’s study. qTerm’s first release is planned to include body temperature, blood oxygen and heart rate vitals. The second release is planned to include blood pressure measurement and enhanced, AI-driven analytics support. The device is accompanied by a smartphone mobile app and synchronized web application to keep measurements history and provide analytics for user's records at a later phase. The web and mobile applications will enable a direct access to the user’s data anywhere around the world including geographical location, statistical and personal information, making it an efficient, remote telemedicine technology. Upon user’s permission, user’s body temperature and location can be anonymously shared with other users to provide health risk proximity alerts. GBT plans to expand its IP protection for qTerm, further adding advanced AI systems and methods concepts in the near future. For more information visit qTerm™ | Vital Signs AI Device.

"We are glad to announce that our qTerm, AI-driven human vitals measurements device, non-provisional patent has received a notice of allowance and is expected to be granted within the next upcoming months. This technology is planned to be marketed and sold for personal and clinics usage and also targeting the telemedicine arena. We consider our qTerm Device intellectual property as one of our major patents and plan to expand its protection along with improving its technology, in efforts to create an intelligent, personal health assistant for everyone" stated Danny Rittman, the Company’s CTO.

There is no guarantee that the Company will be successful in researching, developing or implementing this system. In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched, developed and granted regulatory approval, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps.

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:
Dr. Danny Rittman, CTO
press@gopherprotocol.com

FAQ

What is the significance of the patent notice for GTCH?

The patent notice indicates that GTCH's qTerm device has met necessary criteria for patent protection, which is crucial for its commercialization.

When is the qTerm device expected to be released?

The first release of the qTerm device is planned to include essential vitals measurements, though a specific date has not been provided.

What vitals will the qTerm device measure?

The qTerm device will initially measure body temperature, blood oxygen levels, and heart rate.

What challenges does GTCH face in launching the qTerm device?

GTCH faces challenges in raising sufficient capital and forming strategic partnerships for manufacturing and distribution.

How does the qTerm device support telemedicine?

The qTerm device includes a mobile app and web application that allow users to access their vitals data remotely, enhancing telemedicine capabilities.